Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis

Tanabe, Tomohide; Hoshino, Shintaro; Kawami, Noriyuki; Hoshikawa, Yoshimasa; Hanada, Yuriko; Takenouchi, Nana; Goto, Osamu; Kaise, Mitsuru; Iwakiri, Katsuhiko

doi:10.1007/s10388-019-00676-x

Cited by 19 publications

(15 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This regimen also improved epigas-tric pain and postprandial distress symptoms, that frequently complicate non-erosive GERD (20). Although there are some studies showing the effect of vonoprazan on PPI-resistant GERD, they primarily report the outcomes of patients with PPI-resistant erosive GERD (10,12,22). The present study demonstrated the long-term effectiveness of vonoprazan on PPI-resistant non-erosive GERD as well as erosive GERD.…”

Section: Discussionsupporting

confidence: 58%

See 1 more Smart Citation

Long‑term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor‑resistant gastroesophageal reflux disease

Shinozaki¹,

Osawa

Hayashi

et al. 2021

Biomed Rep

View full text Add to dashboard Cite

Vonoprazan, a novel potassium-competitive acid blocker, results in greater inhibition of gastric acid secretion than proton pump inhibitors (PPI). The aim of this study was to assess the long-term outcomes of patients with PPI-resistant gastroesophageal reflux disease (GERD) treated with vonoprazan. The medical records of patients with symptomatic GERD treated with vonoprazan for 1 year were retrospectively reviewed. Changes in abdominal symptoms were assessed using the Izumo scale, a self-reported questionnaire which is useful in evaluating the symptoms of GERD, epigastric pain, postprandial distress, constipation and diarrhea, and is commonly used in routine clinical practice. A total of 30 patients were included and stratified into a non-erosive (n=22) and erosive group (n=8). At baseline, postprandial distress symptoms were significantly greater in the non-erosive group compared with the erosive group (P= 0.013). Even with vonoprazan therapy, symptoms of GERD in the non-erosive group were refractory compared with the erosive group, and required additional treatment in a larger proportion of patients (45 vs. 13%). GERD symptoms in the non-erosive group significantly improved from baseline and remained better after 1 year of vonoprazan therapy, similar to the erosive group. In addition, vonoprazan improved epigastric pain and postprandial distress symptoms in the non-erosive group, and 1 year of vonoprazan therapy did not aggravate constipation or diarrhea. In conclusion, 1 year of vonoprazan therapy improves GERD symptoms in patients with PPI-resistant GERD.

show abstract

Section: Discussionsupporting

confidence: 58%

“…A recent Japanese prospective study showed that long-term maintenance therapy with vonoprazan for PPI-resistant erosive GERD was effective (22). All patients included in the present study had suffered from persistent, recurrent and/or refractory GERD symptoms over a long period of time.…”

Section: Discussionmentioning

confidence: 87%

Long‑term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor‑resistant gastroesophageal reflux disease

Shinozaki¹,

Osawa

Hayashi

et al. 2021

Biomed Rep

View full text Add to dashboard Cite

show abstract

“…During the 48-week 10-mg-vonoprazan maintenance therapy, the symptomatic non-relapse rates for acid reflux-related symptom score of FSSG and acid reflux score of the Gastrointestinal Symptom Rating Scale at 48 weeks were 70.0 and 72.0%, respec- tively [15]. In another study, no significant difference was noted in the FSSG score between 8 and 52 weeks of 10-mg VPZ administration [16].…”

Section: Gerd Symptomsmentioning

confidence: 93%

“…In 5 open-label prospective studies, vonoprazan 10 mg once daily showed effective 8-week [11], 24-week [6], 48- week [15], and 52-week [13,16] maintenance therapy of healed reflux oesophagitis or erosive oesophagitis refractory to PPIs [6,11,13,15,16]. On-demand therapy using 20-mg vonoprazan tablets is also an effective alternative maintenance therapy for mild reflux esophagitis [17].…”

Section: Efficacy Of Maintenance Therapymentioning

confidence: 99%

Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review

Chinzon¹,

Moraes-Filho²,

Domingues³

et al. 2022

View full text Add to dashboard Cite

Introduction: Vonoprazan has been found to promote a better antisecretory effect addressing acid-related diseases' unmet needs.Aim: To assess if vonoprazan effectively treats patients diagnosed with gastroesophageal reflux disease esophagitis or with peptic ulcers induced by chronic use of aspirin or non-steroidal anti-inflammatory drugs.Material and methods: A literature search was conducted (April/2021) using Medline via PubMed, Cochrane library, Lilacs, Scielo, and Centre for Reviews and Dissemination electronic databases.Results: We retrieved 55 titles. Of these, 13 met the eligibility criteria and were included in this review. Of these 13 articles, 4 were prospective cohort studies, 1 was a follow-up analysis of a preceding prospective study, 1 was a retrospective cohort study, and 6 were randomized clinical trials.Conclusions: Our findings suggest that vonoprazan was effective and non-inferior to proton pump inhibitors in healing and maintaining healed reflux oesophagitis, leading to faster symptom relief. Vonoprazan may also be considered for preventing aspirin-or non-steroidal anti-inflammatory drug-related peptic ulcer recurrence.

show abstract

“…Efficacy and safety of vonoprazan for the management of oesophagitis related to GERD and among patients with low-dose aspirin-or NSAID-induced ulcer were previously assessed in several studies [26][27][28][29][30][31][32][33][34][35][36][37][38][39]. Considering the comparison with PPIs, only studies assessing vonoprazan performance against lansoprazole, which is a potent PPI, were conducted.…”

Section: Vonoprazan: Efficacy and Safety Datamentioning

confidence: 99%

Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review

Domingues¹,

Chinzon²,

Moraes-Filho³

et al. 2023

View full text Add to dashboard Cite

Introduction: A new therapeutic class, potassium-competitive acid blockers (P-CABs), has emerged in Brazil to promote a superior antisecretory effect addressing the unmet needs related to acid-related disease management. Vonoprazan fumarate showed a good safety profile and was approved by the Brazilian regulatory agency -ANVISA.Aim: This narrative review was conducted to review the general concepts regarding P-CABs, focussing on vonoprazan fumarate.Material and methods: A literature search was conducted through April-May 2021 using official databases with a combination of MeSH controlled vocabulary and text words. The authors selected articles that described pivotal and novel insights about P-CABs and vonoprazan fumarate.Results: Vonoprazan is a drug of the P-CABs class newly approved for the management of acid-related diseases in Brazil. P-CABs achieve rapid, potent, and prolonged acid suppression (including night-time) and promise to address some unmet clinical needs in GERD. Furthermore, considering the difficulties encountered in attaining effective symptomatic control -particularly at night -using currently available PPIs, this new drug class is promising.Conclusions: This review brings important information about vonoprazan, a new therapeutic option in Brazil, which may be considered as a valuable tool for managing acid-related diseases.

show abstract

Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis

Cited by 19 publications

References 19 publications

Long‑term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor‑resistant gastroesophageal reflux disease

Long‑term vonoprazan therapy is effective for controlling symptomatic proton pump inhibitor‑resistant gastroesophageal reflux disease

Vonoprazan in the management of erosive oesophagitis and peptic ulcer-induced medication: a systematic review

Potassium-competitive acid blockers, a new therapeutic class, and their role in acid-related diseases: a narrative review

Contact Info

Product

Resources

About